Rentschler Biopharma appoints Veit Bergendahl as COO. Veit Bergendahl will assume operational responsibility for process development, clinical and commercial cGMP manufacturing, engineering and technology, as well as automation in production from April 1, 2026. Rentschler Biopharma has appointed Veit Bergendahl as Chief Operating Officer (COO) and member of the Executive Board. He succeeds Christiane Bardroff, who is taking on a new professional challenge outside the company and will leave the company at her own request during the first quarter of this year. As of April 1, 2026, Bergendahl will be responsible for process development, clinical and commercial cGMP manufacturing, engineering and technology, as well as automation at Rentschler Biopharma. Bergendahl brings more than 20 years of international experience in biopharmaceutical development, manufacturing, and CMC. He has worked in Europe and the USA for renowned pharmaceutical and biotech companies, in contract development and for research institutions. He has excellent knowledge of the entire biopharmaceutical value chain - from early development through clinical supply to commercial production, including international regulatory requirements. His expertise includes the management of complex development and manufacturing processes, site development, including overall operational and commercial responsibility, efficiency improvement, and cooperation with international partners. Nikolaus F. Rentschler, Chairman of the Supervisory Board: "I am very pleased that Veit Bergendahl is taking on the role of Chief Operating Officer as the company enters a phase of further accelerated growth. With his strategic understanding of the biopharmaceutical value chain, his outstanding industry expertise, and many years of international experience in leadership roles, he will make a significant contribution to further strengthening our culture of reliability in a highly demanding market environment. His shared values and strong focus on partnership and sustainable development represent a significant asset for both our company and our clients." "With Veit Bergendahl, whom I hold in the highest regard, we are gaining a highly experienced international leader who will strengthen our operations with his deep expertise and a clear forward-looking perspective," commented Uwe Buecheler, Interim CEO of Rentschler Biopharma. "His comprehensive understanding of the development, manufacturing, and scaling of complex biopharmaceutical products is combined with a strong client focus and the highest commitment to quality. I particularly value his ability to link operational excellence with entrepreneurial thinking, inspiring teams to work toward shared goals. I am convinced that he will further accelerate the positive direction we have taken, especially through his strengths in innovation and operational excellence. I very much look forward to working with him and know that, together with our colleagues in Laupheim and Milford, he will provide important impetus for the continued successful development of Rentschler Biopharma." Veit Bergendahl added: "I am very much looking forward to working with the Executive Board and the team at Rentschler Biopharma. As a family-owned company and leading CDMO, Rentschler Biopharma delivers tailor-made solutions for essential biopharmaceuticals and combines scientific innovation with a strong sense of responsibility toward patients worldwide. It is very important to me to further build on this strong foundation. I aim to support and strengthen the dedicated teams in Laupheim and Milford, further enhance the robustness and efficiency of processes, and leverage new technologies to further advance operational excellence and develop long-term client-partnerships based on the highest levels of quality and reliability." Before joining Rentschler Biopharma, Bergendahl worked at Boehringer Ingelheim for 13 years in various functions with increasing responsibility. Most recently, as Head of Clinical Supply Biologicals, he was responsible for the commissioning and go-live of the Biologicals Development Center at the research and development site in Biberach, and since 2023, he has been in charge of the single-use facility for clinical production with 2x2,000L bioreactors. Previously, as Executive Director Upstream Manufacturing, he managed a large-scale production facility (10x15,000L). Previous positions at Boehringer ranged from managing transfer projects in clinical phase I to commercial processes in contract manufacturing. His other professional stations were at Miltenyi Biotec and Roche (Germany). In the USA, he conducted research at the University of Wisconsin and held management positions at Cellular Dynamics International. Bergendahl holds a degree in biochemistry and a doctorate in biology from Philipps University, Marburg. Company. Erwin-Rentschler-Str. 21 88471 Laupheim Germany

EQS-News: Rentschler Biopharma SE / key word(s): personnel Rentschler Biopharma appoints Detra Glinatsis as Head of Business Development U.S. 22.01.2026 / 13:00 CET/CEST the issuer is solely responsible for the content of this announcement. Rentschler Biopharma appoints Detra Glinatsis as Head of Business Development U.S. Laupheim (Germany), Milford, MA (USA), January 22, 2026 - Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, today announced that Detra Glinatsis has rejoined the company as Head of Business Development U.S. In this newly created role, Ms. Glinatsis will lead all business development activities related to the U.S. market. She reports to Dr. Patrick Meyer, Global Head of Business Development, and is based at the company's site in Milford, MA. Dr. Patrick Meyer, Global Head of Business Development at Rentschler Biopharma, commented: "I am excited to have Detra rejoin Rentschler Biopharma to serve in this important role. Her career is a true testament to her expertise, client-centric mindset, and ability to build long-lasting, meaningful partnerships. The United States is a cornerstone of our commercial strategy, and our presence in Milford, MA enables us to bring Rentschler Biopharma's innovative thinking and development strength directly to the doorstep of our clients. In the past two years, we have successfully transferred one post-PPQ commercial program to the site, are advancing three additional programs toward PPQ, and initiated manufacturing for six new products in 2025 - clear proof of the momentum Detra will now help to accelerate. Expanding our U.S. business is critical to the next growth stage of our corporate strategy, and Detra, with her commitment to excellence and exceeding client expectations, is the ideal person to lead our U.S. business development activities." Detra Glinatsis brings over twenty years of sales and business development experience in the pharmaceutical, biotech and contract manufacturing industries. She rejoins Rentschler Biopharma from Northway Biotech, where she was Vice President, Business Development. She previously held roles of increasing responsibility at AGC Biologics, Sartorius, Gallus BioPharmaceuticals, and Avecia Biologics, as well as Rentschler Biopharma, where, earlier in her career, she was Senior Director, Business Development. Ms. Glinatsis holds a B.S. in biology from the University of Akron. Detra Glinatsis, Head of Business Development U.S., said: "I am thrilled to come back to Rentschler Biopharma as the company continues to grow its U.S. business. Together with the team, I look forward to building on the success that the company has achieved with the Milford site expansion and continuing to enhance the Rentschler Biopharma brand in the U.S. The company has a long-standing reputation for top quality and reliability, and I am excited to be working with such a talented team with a coveted track record." About Rentschler Biopharma SE Rentschler Biopharma is a leading contract development and manufacturing organization (CDMO) focused exclusively on client projects. The company offers process development and manufacturing of biopharmaceuticals as well as related consulting activities, project management and regulatory support. Rentschler Biopharma's high quality is proven by its long-standing experience and excellence as a solution partner for its clients. A high-level quality management system, a well-established operational excellence philosophy and advanced technologies ensure product quality and productivity at each development and manufacturing step. Rentschler Biopharma is a family-owned company with about 1,400 employees, headquartered in Laupheim, Germany, with operations in Milford, MA, USA. In 2024, the company joined the United Nations Global Compact, emphasizing Rentschler Biopharma's focus on sustainability. For further information about the company, please visit www.rentschler-biopharma.com. Follow Rentschler Biopharma on LinkedIn. Contact: Rentschler Biopharma SE Dr. Latika Bhonsle-Deeng Global Head of Communications Phone: +49-7392-701-467 [email protected] For high-resolution images, please contact [email protected]. 22.01.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. The issuer is solely responsible for the content of this announcement. The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. View original content: EQS News

Rentschler Biopharma Inc. named Manufacturer of the Year for Central Massachusetts. * Company honored by state's Legislative Manufacturing Caucus for outstanding leadership and contributions to the manufacturing sector * State-of-the-art production line is bringing in new clients, new projects, new indications Rentschler Biopharma, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, today announced that its U.S. subsidiary, Rentschler Biopharma Inc., has been selected as the Manufacturer of the Year for Central Massachusetts across all industries. The award was presented at the 10th Annual Manufacturing Awards Ceremony, hosted by the state's Legislative Manufacturing Caucus, on October 21, 2025, at Gillette Stadium in Foxborough, MA. The event honored manufacturers from across the state for their outstanding leadership roles and contributions to the manufacturing sector. Massachusetts has become a strong leader in advanced manufacturing, and the event celebrated this achievement, highlighting the need for government and industry to continue to work together to drive innovation. State Senator Becca Rausch, who nominated Rentschler Biopharma for the award, stated: "I am proud to nominate Rentschler Biopharma for the 10th Annual Massachusetts Manufacturing Awards. Collaborating with state and local organizations, Rentschler Biopharma has developed a pipeline for local workers to begin careers in life sciences and biotech manufacturing, and their state-of-the-art facility in Milford brings good jobs to the MetroWest region. Additionally, Rentschler Biopharma is a strong community partner and dedicated to environmental sustainability, a commitment with increasing significance due to the ongoing impacts of climate change." Tom Roberts, President of Rentschler Biopharma Inc. and General Manager U.S., said: "We are honored to receive this award and proud to be part of the Massachusetts biopharma and manufacturing communities since 2019. With our new production line in Milford now fully operational, we've entered a new phase of growth - welcoming new clients, launching new projects, and expanding our support for existing international partners. This recognition reflects the dedication of our entire team and the strength of our U.S. capabilities. At Rentschler Biopharma, we are committed to being a trusted partner - delivering reliable, high-quality solutions that help our clients bring innovative, life-changing treatments to patients." The new production line represents the largest expansion in the company's more than 150-year history. It became fully operational last year, adding 22,000 square feet of manufacturing cleanroom space to the existing Milford site and housing four 2,000 L single-use bioreactors. It was the largest expansion in the company's more than 150-year history, doubling Rentschler Biopharma's global cGMP capacity. The facility is developing and manufacturing a variety of therapeutics across multiple modalities and disease areas, including oncology, hematology, musculoskeletal, cardiovascular, and organ failure. Corporate spokesperson. Rentschler Biopharma SE